Development of Ketamine Metabolites in the Treatment of Depression

Bio: Philip Wang is a fifth year medical student at the Cleveland Clinic Lerner College of Medicine who conducted a research year at the Experimental Therapeutics and Pathophysiology Branch of the National Institute of Mental Health in the lab of Dr. Carlos Zarate. Dr. Zarate conducted the first trial of ketamine in treatment resistant depression and the goal of the lab is to develop novel medications for treatment-resistant depression and bipolar disorder.

This event can be attended in person or virtually. Please sign up for an email with further details about the physical location and Microsoft Teams info. 

This event has been changed to start at 5pm.